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Abstract
Genomic research has the potential to increase knowledge in health sciences, but the process has to ensure the
safety, integrity and well-being of research participants. A legal framework for the conduct of health research in
Zambia is available. However, the ethical, policy and regulatory framework to operationalise genomic research
requires a paradigm shift. This paper outlines the current legal and policy framework as well as the ethics
environment, and suggests recommendations for Zambia to fully benefit from the opportunity that genomic
research presents. This will entail creating national research interest, improving knowledge levels, and building
community trust among researchers, policymakers, donors, regulators and, most importantly, patients and research
participants. A real balancing act of the risk and benefits will need to be objectively undertaken.
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Background
Genomics is defined as the study of genes and their
functions, and related techniques [1, 2]. The human gen-
ome project – an international, collaborative research
program – has provided a complete map and under-
standing of the human genome [3, 4]. With the analysis
of the human genome comes the opportunity to study
biomedical research at a more finite level than has been
previously possible. Advancements in technology have
made it possible to rapidly analyse genetic information
and elucidate its research and clinical relevance. This
has given way to predictions that vaccines, drugs and
other interventions will eventually be tailored according
to an individual’s genetic make-up [5, 6]. The potential of
genomics research to improve health outcomes of popu-
lations cannot be underestimated, and it is therefore im-
portant to determine the best way to progress quickly
[6, 7]. However, there remains scepticism regarding the
added value of genomics in disease prevention, with the
notion that, rather, reinforcing population-based ap-
proaches to prevention, especially for diseases with
known environmental causes, is more beneficial [8].
Khoury et al. [9] argue that applied genomic research is as
important for conditions with environmental causes as for
those without known environmental determinants.
Genome-wide association studies are among the gen-
omic tools being used to identify the genetic contributors
of common disorders such as diabetes, cardiovascular dis-
ease, and prostate cancer [10]. To date, only seven such
studies have been documented to have been conducted
exclusively on African participants [11, 12], and a few other
studies have included some African participants [13–16].
The potential health benefits of genomic research are
not always immediately tangible [17]. Genetic counsel-
ling and testing for hereditary syndromes are some of
the few evidence-based applications that have become
part of routine healthcare [18–20]. Therefore, a compre-
hensive genomic research agenda must be adopted in
order to aid the translation of genomic research findings
into healthcare in a way that maximizes health benefits
and minimizes harm to individuals and populations.
Khoury et al. [21], in their review paper, provide a
four-phase continuum framework for the translation of
genomic research into healthcare and prevention that re-
volves around the development of evidence-based guide-
lines. The Clinical and Translational Research Institute
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in San Diego has implemented a model adapted from
this framework [22]. However, Pawson et al. [23] suggest
an alternative approach; their method focuses on context
and external validity, and seeks to answer the questions:
which intervention, for which problem, which set of pa-
tients is the intervention most effective for, and what
outcome does it produce? Genomic research is both an
opportunity and a challenge for all stakeholders, ranging
from legislators, policymakers, researchers, ethics com-
mittees, and research participants, as there is an urgent
need to balance the obligations to respect and protect
research participants with social interest in advancing
beneficial research [24].
In Zambia, genomic research, although rare, is an
evolving science and the studies conducted so far have
mainly focused on the key genetic determinants of the
responses to HIV infection in a cohort of discordant
couples [25] and on the sequencing of Bacillus anthracis
outbreak strain CZC5 during the Chama district An-
thrax outbreak of 2011 [26]; both these studies being im-
portant for the advancement of health service provision,
health promotion, research and, subsequently, disease
elimination. However, the cardinal issue is to ensure
there is adequate regulation, an enabling environment
and consensus on what constitutes genomics and in-
formatics as argued by Lyon and Segal [6]. In this article,
we discuss genomic research in Zambia, interrogating
the issues pertaining to the ethics, policies and regula-
tory frontiers, and discussing the challenges being faced
in this century, with recommendations for improving
the status quo.
Ethics environment
Genomic research is fraught with unique ethical chal-
lenges which will need the attention of regulators. These
issues may not be adequately dealt with by current local
and international guidelines and legal frameworks, and
concern, in particular, current guidelines related to in-
formed consent procedures, withdrawal from a research
study, disclosure of research results which may result in
adverse consequences, release of data to the public result-
ing in loss of privacy, and possible commercialisation of
results [27]. Foremost among the ethical challenges to
genomic research in Africa are the sensitivities and ques-
tions raised by communities based on their previous expe-
riences and regional/cultural beliefs and practices [28].
All Research Ethics Committees (RECs) or Institutional
Review Boards (IRBs) are supposed to be registered with
the National Health Research Council, in accordance with
the Health Research Act No. 2. 2013 of the Laws of
Zambia, and should adhere to these principles.
According to the East, Central and Southern Africa
Health Community assessment [29], a number of weak-
nesses/non-conformities in the Zambian ethics system
were identified, including the lack of an on-going quality
improvement system, no full-time employees assigned to
the IRB/REC, no specific application form available for
submission of protocols for approval, and protocols were
not reviewed by regional or international bodies. There
was no policy on the review process. In addition, the
qualifications of the author to conduct the research were
not taken into consideration. The interval of continued
review for risky studies was not determined, neither was
the input of a Community Advisory Boards or the avail-
ability of a product or utility to the community upon com-
pletion of the study taken into consideration. Community
Advisory Boards are often associated with the review of
clinical research ethics with regards the human subjects of
research and serve as an aspect of community-based par-
ticipatory research [30, 31]. In order for genomic research
in Zambia to be successful, issues such as community en-
gagement, broad consent, and the implications of sharing
genetic information need to be debated and the potential
risks of stigmatisation and harm need to be considered
carefully [32]. Ultimately, these ethical challenges need to
be weighed against strategies and approaches for making
use of genomic research to address the high burden of dis-
ease in Zambia.
According to the Health Research Act No. 2 of 2013
of the Laws of Zambia, consent needs to be specific;
therefore, broad and ‘open’ or ‘unrestricted’ consent is
not possible in Zambia, and neither is long-term storage
of samples. To what extent will it be necessary, for
example, to modify current guidelines on informed
consent to provide for research in future, unknown
studies – which is a hallmark of bio-banking and genomic
research? What about the right of the participants to with-
draw from a study? The level of anonymity of genetic in-
formation in a database, the rights of participants and
relatives to be informed of potential diseases, as well as
many other important ethical issues related to genomic re-
search will need to be addressed by regulations that are
currently not in place or in use for ordinary research. The
need for all the stakeholders to maintain the public trust
cannot be underestimated. Any perceived breech of this
trust will only serve to create an atmosphere of mistrust
between participants and the research community, as well
as with the regulatory agencies, and make it more difficult
to conduct future research [25]. Some genetic information
could violate the privacy and reputations of individuals or
entire social groups, leading to discrimination. Safeguards
will therefore be necessary to protect the welfare and priv-
acy of participants of genomic research [33, 34].
Attempting to apply universal ethical principles to gen-
omic research in a multicultural world with diverse health-
care systems and considerable variation in standards of
healthcare presents yet another challenge. According to the
International Ethical Guidelines for Biomedical Research
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Involving Human Subjects [35], research involving hu-
man subjects must not violate any universally applic-
able ethical standards, but acknowledge that, in
superficial aspects, the application of the ethical prin-
ciples, for instance, in relation to individual autonomy
and informed consent, needs to take account of cul-
tural values while fully respecting the ethical stan-
dards. Application of the universal principles of
research ethics, albeit within a local context, will re-
quire well-trained individuals at several levels, includ-
ing researchers and ethics committees, as well as
regulatory agencies.
Genomic research is a specialised and very knowledge-
intensive field [36]. Limitations in technical expertise
and institutional capacity have constrained the progress
of health research in Zambia. There is a clear need for a
pool of technical expertise and improved funding for re-
search and ethics monitoring if genomic research is to
be effectively implemented. Members of RECs will re-
quire training on the intricacies of the legal and ethical
implications of genomic research. Infrastructure will
need to be provided for various levels of training in the
relevant concepts of the applications of genomic re-
search given the genetic literacy knowledge gap. Train-
ing members of IRBs/RECs, as well as interested
researchers, will help to ensure informed ethical review
processes for genomic studies. Public lectures, as well as
information sessions, could also be used to educate the
community and gauge the public perception of genomic
research [37].
Policy environment
The National Health Policy [38] provides for several
measures with regards to health research, which include
the provision of adequate funding for priority health re-
search, linkage and integration between research, policy
and action, construction of a national database and re-
pository, as well as the development and implementation
of an appropriate legal framework to guide research con-
duct. These measures are further highlighted in the
National Health Research Policy [39].
Relevant policy frameworks will be required to guide
the boundary within which genomic research can be ap-
plied in order to curtail scientific malpractice while en-
suring the maximum benefits of health improvements.
Additionally, it will be necessary to ensure that health
research and associated outcomes primarily address the
national interests.
The historical norm in Africa has been that the flow of
samples and data has only occurred in one direction –
out of Africa – creating a sense of mistrust and exploit-
ation [40]. Genomic policy initiatives must, therefore,
seek to change the notion that the problems faced by
low- and middle-income countries such as Zambia can
be solved by providing greater access to global know-
ledge resources and recognise the need for these coun-
tries to actively participate in knowledge generation.
Given the high costs associated with genomic research,
it is imperative that the formulation of relevant policies
entails public and/or external funding not only for the
research but for infrastructure development as well.
Local resource allocation to genomic research will be ne-
cessary as a demonstration of commitment to improve
capacity for genomic research, in addition to initiatives
from the NIH and Welcome trust [40, 41]. Local funding
will also improve ownership and local interest.
Policies around genomic research will need to take
into account the requirement for a publishing system
that will drive the dissemination of research knowledge
into locally accessible journals rather than high-cost
international journals that effectively inhibit the ability
of research to have meaningful impact on development.
Open access publishing offers swift dissemination of re-
search results, especially to places where these results
can have meaningful impact. The existing conflict be-
tween open access dissemination of scientific discoveries
and the protection of intellectual property rights, how-
ever, needs to be addressed if scientific discoveries are to
be translated into national development, more so in the
case of genomic research. A 2009 study on open access
publishing [42] found that about 83% of the respondents
supported the basic principle of open access and 90% in-
dicated their willingness to publish in such journals. Ap-
proximately 68% of the respondents said that they would
support the policies of research institutes, the govern-
ment and donor agencies funding research to have pub-
lications from research activities deposited in open
access institutional repositories.
Genomic research information also begs the question of
privacy and confidentiality given that genomic information
cannot be completely delinked from the individual [24].
Dissemination and access to genomic information, there-
fore, needs careful control in order to prevent identifica-
tion of individuals or families. In a bid to formulate
policies that address the issue, restrictive data release may
be the way to go. This would regulate who has access to
sensitive genomic information and what the information
would be used for. Sound public policies will also need to
be formulated in the area of both the provision and com-
mercialisation of products of genomic research such as
genomic tests. A 2003 review meeting by the Food and
Drug Administration found that, although direct to con-
sumer advertisements of genomic research products do
tend to increase public awareness about diseases, they fail
to accurately convey risk information [43]. Thus, the need
for an appropriate legal and regulatory governance frame-
work is imperative in order to address these and many
other critical ethical issues [44].
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Legal framework
Looking back on the lessons learnt from research projects
such as the Mazabuka Microbicide Research Project [45]
and the passing of the National Health Research Act No.
2 of 2013 [46], it is clear that much needs to be done to
prepare the legal landscape for genomic research in
Zambia. The only piece of legislation that currently covers
genomics is the Biosafety Act No. 10 of 2007 [47], which
focuses mainly on genetically modified organisms or prod-
ucts, with a strong emphasis on agriculture. Zambia’s lack
of directly pertinent genomic research regulation legisla-
tion, however, does not warrant concern, given the broad
protection granted through the current National Health
Research act [46]. The Act, in parts V and VI, provides a
regulatory framework for health research involving
humans or animals. It stipulates that: “biological material
for health research purposes may only be collected with the
written consent of the individual, […] these materials may
not be collected for any unspecified future health research
activity or unspecified storage, [and that] Bio-banks shall
be designated as such by the Minister”. Part X of the act
goes on to address issues regarding intellectual property
rights. However, the Act does not make specific mention
of genomics. The Policy, Monitoring and Research Centre
conducted an analysis of the National Health Research
Act and concluded that “the Act had the potential to im-
prove public health, labour productivity, create employ-
ment and promote economic growth”. It went on further to
highlight some of the challenges likely to be faced in the
implementation of the act, namely the high cost of
implementation and the creation of lengthy bureau-
cratic processes which may work against research ad-
vancement [48].
In order to provide a comprehensive legal mandate for
genomic research, the existing pieces of legislation will
require extensive review as has been done elsewhere in
the United States, Europe, Asia, and Africa [49–53].
Massive changes, repeals and re-enactments of legisla-
tion pertaining to genomic research in Zambia will have
to be undertaken creating an overhaul of the legal land-
scape; hence, the application of information from gen-
omic research in health and non-health sectors is likely
to cause a legal tsunami.
Regulatory challenge
The National Health Research Act No. 2 of 2013 [46]
makes provision for powers of the National Health
Research Authority to, among others, withdraw the ac-
creditation of a health researcher or research institution;
ban health researchers and research institutions from
carrying out research in Zambia; stop an ongoing health
research activity; inspect any institution or site approved
for the conduct of health research, including databases
and bio banks; and to confiscate, impound and destroy,
where necessary, biological materials obtained by any
person in contravention of any provision of the Act.
Genomic research presents both national and inter-
national regulatory challenges. To think that such an
area with great commercial, social, security and legal im-
plications will be easy to regulate would be presumptu-
ous. The various community engagement strategies will
require monitoring so that effective ones can be adopted
as best practices [54]. The regulatory challenge is based
on the fact that, historically, the systems for regulation
of research activities are weak with equally ineffective
mechanisms to monitor research activities following ethics
clearance. This makes it almost impossible for regulatory
agencies in the country to guarantee the protection of the
rights of research participants. This situation is aggravated
by limited national legislation governing genomic research.
With the availability of genomic information comes
the possibility of discrimination against individuals. In-
formation about disorders tends to be of great interest
to third parties such as insurance companies, law en-
forcement agencies or employers [55]. Regulation will be
required for comprehensive protection of persons from
genetic discrimination that may result from the abuse of
sensitive genomic information. One example of regula-
tion against genetic discrimination is the United State’s
Genetic Information Non-discrimination Act of 2008
[56], which was passed into law to protect Americans
against discrimination based on their genetic informa-
tion when it comes to health insurance and employment.
Additionally, the indiscriminate and uncontrolled use
and exportation of human tissues and fluids has a bear-
ing not only on human rights but poses a danger to bio-
safety and security of citizens. Thus, a multi-sectoral
response to genomic research regulation may in the long
run be more effective than a sectoral one.
Clear recommendations on how to deal with malprac-
tices involving funders or researchers will be required. It
is therefore evident that this is an area requiring not
only ongoing consultations with all stakeholders, but al-
location of financial and technological capacity to mount
effective regulatory approaches.
The opportunities at hand
The health improvement, cost efficiency of prevention of
negative health consequences and the ease with which
health conditions can be genetically detected before
phenotypic expression is enormous. Genomic research
has contributed to clinical advances in the study of rare
diseases; the discovery of a single gene mutation in sev-
eral instances has led to new therapeutic approaches to
conditions that have perplexed clinicians for years [57].
Clinicians are now able to minimize the risk of prescrib-
ing the wrong dose by testing a patient’s genome for
relevant variants in order to establish the appropriate
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dosage of medications, thereby making treatment more
effective [58]. Furthermore, microbial genomics prom-
ises to improve the management of infectious diseases
[59] and, with Zambia seeing a rise in the burden of
non-communicable diseases such as cardiovascular dis-
eases, diabetes, and cancers, genomics certainly offers a
new frontier in healthcare.
The Zambia Health Research Act provides for the for-
ging of health research collaborations while building
local expertise by stipulating that, “Health research shall
not be conducted without the inclusion of a Zambian,
who resides in Zambia, on the research team as a princi-
pal or co-principal researcher” [46]. Opportunities for
collaborative ventures, if well nurtured, can improve our
understanding of health from a broader perspective.
One such collaboration will see all African genomic pro-
jects sending a portion or all of their samples into one of
several bio-banks. Guidelines and policies will be devel-
oped by the bio-bank working groups to govern sample
movement [60].
On a secondary level, genomic research is an excellent
platform for job creation, product development and
innovation. Lessons can be drawn from the United
States and India, where genomic research has signifi-
cantly contributed to these countries’ economies – in
the United States alone, Federal research investment has
helped to generate nearly $1 trillion in economic im-
pacts to date [61].
Recommendations for action
In order for Zambia to fully benefit from the opportun-
ity that genomic research presents, review or update of
the current legal/policy framework will be necessary.
There is an urgent need for the development of detailed
guidance documents for the operationalisation of the
policies. As has been already highlighted, any breach of
trust, real or perceived, between the participants, com-
munity and regulators, can have a profound effect on
the future of genomic research in Zambia. It is, there-
fore, imperative that trust is developed among stake-
holders and that headway is made in demystifying
genomic research for lay people.
Furthermore, if the challenges associated with the an-
ticipated high costs of genomic research are to be over-
come, adequate resources must be allocated to support
ongoing scientific enquiry in this dynamic field. Training
of local staff is one way to ensure that the benefits of
genomic research to both the research community and
public are optimised. The need to collaborate with rele-
vant regional or international bodies towards creation of
transparent and mutually beneficial information gener-
ation programs cannot be overstated. As it stands cur-
rently, legislation of research and ethics guidance is
restrictive – developed as such to prevent exploitation
and promote fairness. This has, however, had the unfor-
tunate effect of limiting opportunities for African scien-
tists to engage in international collaborations and use
novel research methods. The solution lies in striking a
balance between developing regulation that appropri-
ately protects the interests of African researchers and re-
search participants, and at the same time does not limit
or restrict opportunities that could ultimately be benefi-
cial for both.
Conclusion
There is much room for improvement when it comes to
the current research governance mechanisms, especially
with regard to governing boards and research monitoring
systems as well as reporting mechanisms and code of con-
duct adherence. Building capacity for genomic research will
require input from multiple sectors in order to develop the
appropriate regulatory frameworks (including the establish-
ment of IRBs/RECs), building and maintaining physical in-
frastructure, and investing in human resources, equipment,
and training as well as demand and supply for enhanced
scientific research, based on a conviction that research, and
particularly genomic research, can improve the lives of
people and spur economic development.
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